Éric Lévesque
Chercheur universitaire clinicien
Axe Endocrinologie et néphrologie
Publications
-
article Petrylak DP, Ratta R, Matsubara N, Korbenfeld E, Gafanov R, Mourey L, Todenhöfer T, Gurney H, Kramer G, Bergman AM, Zalewski P, De Santis M, Armstrong AJ, Gerritsen W, Pachynski R, Byun SS, Retz M, Levesque E, McDermott R, Bracarda S, Manneh R, Levartovsky M, Li XT, Schloss C, Poehlein CH, Fizazi K
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
J Clin Oncol 43 (14), 2025.
-
article Nazha S, Tanguay S, Kapoor A, Jewett M, Kollmannsberger C, Wood L, Bjarnason GAG, Heng D, Soulières D, Reaume MN, Basappa N, Lévesque E, Dragomir A
Cost-utility of Sunitinib Versus Pazopanib in Metastatic Renal Cell Carcinoma in Canada using Real-world Evidence
Clin Drug Investig 38 (12), 2018.
-
article Saad F, Winquist E, Hubay S, Berry S, Assi H, Levesque E, Aucoin N, Czaykowski P, Lattouf JB, Alloul K, Stewart J, Sridhar SS
Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone
Can Urol Assoc J 10 (3-4), 2016.
Projects
- UGT2B28 IS A PROGNOSTIC AND PREDICTIVE BIOMARKER IN PROSTATE CANCER, from 2023-09-01 to 2025-08-31
- Découverte de biomarqueurs pronostiques et prédictifs en cancer de la prostate., from 2024-05-22 to 2027-05-22
- Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression, from 2021-09-01 to 2023-08-31